Answers are grounded in this paper and cite their sources.
CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated remarkable efficacy in treating relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (B-NHL) [ 1 , 2 , 3 , 4 , 5 ]. Two Food and Drug Administration approved CAR-T products are commercially available for B-ALL, and four for B-NHL. However, its availability for Malaysian patients remains limited due to high costs and the absence of approved products. Plutonet Sdn Bhd has introduced locally manufactured CD19-CAR-T cells to overcome these challenges, providing an affordable and accessible solution for R/R B-ALL and B-NHL patients in Malaysia who have failed standard therapies. We report the clinical outcomes of 30 patients treated with a new local CAR-T cell product developed locally. Two open-label, single-arm prospective phase II trials were conducted at Pusat Terapi Sel, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (UKM) from 2019 to 2025 in R/R B-ALL and B-NHL treated with autologous CD19-41BB CAR-T cells (PP CAR-T). PP CAR-T characteristics, study methods, and enrollment details are described in Supplementary Materials . A total of 73 patients were enrolled, of whom 56 proceeded to apheresis (Fig. 1 ). PP CAR-T cells were manufactured for 31 patients and ultimately administered to 30 patients (41% of the total cohort). Approximately one-quarter of enrolled patients ( n = 17) did not undergo apheresis due to rapid disease progression leading to death ( n = 8) or inadequate T-cell fitness as determined by a failed T-cell assimilation test ( n = 7). Among those who underwent apheresis, the main reason for not receiving CAR-T therapy was cancer-related mortality ( n = 19; 6 B-ALL, 13 B-NHL), with only one case of manufacturing failure (3.2%). These high attrition rates (58.9%) underscore the critical importance of early referral—before disease progression precludes eligibility for clinical trial participation—and timely T-cell collection to preserve T-cell fitness and improve the likelihood of CAR-T treatment delivery. Fig. 1: Overall treatment response in 29 patients (B-ALL; 8; B-NHL: 21) treated with PP CD19 CAR-T cell therapy. a B-NHL, b B-ALL. Full size image The median time from apheresis to start of culture was 61.5 days (11–241), while the median time for cell culture was 14 days. The median dose of CAR-T cells infused were 2 × 10 6 /kg (1.0–2.85), in which most (24 of 30) patients received fresh CAR-T cells. Safety and efficacy were assessed at the data cutoff of March 31, 2025. Results were compared with those of commercial 4-1BB co-stimulated CAR T-cell products, specifically Tisagenlecleucel (Tisa-cel). The median follow-up period for the overall cohort was 12.5 months (0.5–42.5 months). Table 1 shows patient and disease baseline characteristics and outcomes of PP CAR-T therapy. Table 1 Patient baseline characteristics and PP CAR-T cell treatment outcomes. Full size table Among the eight patients with B-ALL, two were Philadelphia chromosome-positive (Ph+). Most of the B-ALL patients (75%) had primary chemorefractory disease. Three patients had received 3 to 4 prior lines of therapy, while four had undergone allogeneic hematopoietic stem cell transplantation (HSCT), and one had received an autologous HSCT. Among the 22 patients with B-NHL, the majority were diagnosed with diffuse large B-cell lymphoma (DLBCL), including five cases classified as double- or triple-expressor lymphomas. Half of the patients had primary chemorefractory disease, and a similar proportion had received three to four prior lines of therapy. Six had previously undergone autologous HSCT. At baseline, elevated serum LDH levels were observed in 50% of patients, while 11 presented with extranodal involvement, and 3 had bone marrow infiltration. Further details on disease subtypes, median number of prior treatments, and other relevant disease and patient characteristics are summarized in Table 1 .
No takes yet. Share an insight, caveat, or question.
Fadilah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: